Trade SpringWorks Therapeutics, Inc. - SWTX CFD

SpringWorks Therapeutics, Inc. Company profile

About SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. It has a portfolio of small molecule targeted oncology product candidates and are advancing two clinical trials in rare tumor types, as well as other programs addressing genetically defined cancers. Its product candidate is nirogacestat, is an oral, small molecule gamma secretase inhibitor (GSI) in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Its second product candidate is mirdametinib, an oral, small molecule MEK inhibitor in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a rare tumor of the peripheral nerve sheath that causes pain and disfigurement, and that most often manifests in children.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, SpringWorks Therapeutics Inc revenues decreased from $35M to $0K. Net loss increased from $45.6M to $173.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Biopharmaceutical segment loss increase from $46.3M to $173.5M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.05 to -$3.59.